Valeant Pharmaceuticals International (VRX) Reaches New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Valeant Pharmaceuticals International ( VRX) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Valeant Pharmaceuticals International as such a stock due to the following factors:

  • VRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $296.8 million.
  • VRX has traded 6,490 shares today.
  • VRX is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in VRX with the Ticky from Trade-Ideas. See the FREE profile for VRX NOW at Trade-Ideas

More details on VRX:

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. VRX has a PE ratio of 76. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Valeant Pharmaceuticals International has been 3.0 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $77.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.85 and a short float of 2.4% with 4.18 days to cover. Shares are up 59.1% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 8.0%. Since the same quarter one year prior, revenues rose by 16.1%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • VALEANT PHARMACEUTICALS INTL reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, VALEANT PHARMACEUTICALS INTL turned its bottom line around by earning $2.67 versus -$2.62 in the prior year. This year, the market expects an improvement in earnings ($11.10 versus $2.67).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 426.1% when compared to the same quarter one year prior, rising from -$22.60 million to $73.70 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, VALEANT PHARMACEUTICALS INTL's return on equity exceeds that of both the industry average and the S&P 500.
  • Net operating cash flow has slightly increased to $491.10 million or 1.40% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -21.42%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)